M. O'Shaughnessy

Julio S. G. Montaner, Peter Phillips, R. Hogg, 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

The antiviral effect of ritonavir and saquinavir incombination amongst HIV‐infected adults: results from a community‐based study

R. Hogg, J. Montaner, M. Schechter, 1998, AIDS.

Surviving the sex trade: A comparison of HIV risk behaviours among street-involved women in two Canadian cities who inject drugs

M. Schechter, J. Bruneau, M. O’Shaughnessy, 2003, AIDS care.

Females Experiencing Sexual and Drug Vulnerabilities Are at Elevated Risk for HIV Infection Among Youth Who Use Injection Drugs

M. Schechter, M. Tyndall, Kathy Li, 2002, Journal of acquired immune deficiency syndromes.

Stability of dried blood spot specimens for detection of human immunodeficiency virus DNA by polymerase chain reaction

M. Gill, S. Cassol, T. Salas, 1992, Journal of clinical microbiology.

Prescribing practices in a population-based HIV postexposure prophylaxis program

R. Hogg, J. Montaner, P. Braitstein, 2002, AIDS.

Modelling the Potential Economic Impact of Viral Load—Driven Triple Drug Combination Antiretroviral Therapy

B. Yip, R. Hogg, J. Montaner, 1998, PharmacoEconomics.

Prevalence and correlates of untreated human immunodeficiency virus type 1 infection among persons who have died in the era of modern antiretroviral therapy.

R. Hogg, J. Montaner, M. Schechter, 2003, The Journal of infectious diseases.

Elevated rates of antiretroviral treatment discontinuation among HIV-infected injection drug users: implications for drug policy and public health

Julio S. G. Montaner, B. Yip, R. Hogg, 2004 .

Higher baseline levels of plasma human immunodeficiency virus type 1 RNA are associated with increased mortality after initiation of triple-drug antiretroviral therapy.

P. Harrigan, B. Yip, R. Hogg, 2003, The Journal of infectious diseases.

Rates of disease progression among human immunodeficiency virus-infected persons initiating multiple-drug rescue therapy.

P. Harrigan, B. Yip, R. Hogg, 2003, The Journal of infectious diseases.

Is there a baseline CD4 cell count that precludes a survival response to modern antiretroviral therapy?

Evan Wood, P. Harrigan, B. Yip, 2003, AIDS.

Age, Adherence and Injection Drug use Predict Virological Suppression among Men and Women Enrolled in a Population-Based Antiretroviral Drug Treatment Programme

B. Yip, R. Hogg, J. Montaner, 2002, Antiviral therapy.

Antiviral effect of AZT versus stavudine in combination with lamivudine and indinavir in the context of a populational study.

R. Hogg, J. Montaner, B. Yip, 1999, Journal of Acquired Immune Deficiency Syndromes.

Comparison of Costs of Strategies for Measuring Levels of Human Immunodeficiency Virus Type 1 RNA in Plasma by Using Amplicor and Ultra Direct Assays

P. Harrigan, R. Hogg, J. Montaner, 1998, Journal of Clinical Microbiology.

Do dual nucleoside regimens have a role in an era of plasma viral load-driven antiretroviral therapy?

R. Hogg, J. Montaner, M. Schechter, 1998, The Journal of infectious diseases.

B. Yip, R. Hogg, J. Montaner, 2004, Quality of Life Research.

A decade of research on the natural history of HIV infection: Part 2. Cofactors.

R. Hogg, J. Montaner, M. Schechter, 1996, Clinical and investigative medicine. Medecine clinique et experimentale.

Indirect costs of HIV/AIDS mortality in Canada

R. Hogg, J. Montaner, M. Schechter, 1994, AIDS.

CCR5Δ32 and promoter polymorphisms are not correlated with initial virological or immunological treatment response

P. Harrigan, R. Hogg, J. Montaner, 2001, AIDS.

Antiretroviral therapy: 'the state of the art'.

R. Hogg, J. Montaner, M. O’Shaughnessy, 1999, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

Toronto street youth and HIV/AIDS: prevalence, demographics, and risks.

M. O’Shaughnessy, M. Fearon, S. Read, 1999, The Journal of adolescent health : official publication of the Society for Adolescent Medicine.

Interventional cardiovascular procedures among HIV-infected individuals on antiretroviral therapy 1995–2000

A. Levy, B. Yip, R. Hogg, 2003, AIDS.

Total Lymphocyte Count as a Possible Surrogate of Cd4 Cell Count to Prioritize Eligibility for Antiretroviral Therapy among HIV-Infected Individuals in Resource-Limited Settings

B. Yip, R. Hogg, J. Montaner, 2002, Antiviral therapy.

The Cost Effectiveness of Antiretroviral Regimens for the Treatment of HIV/AIDS

B. Yip, R. Hogg, J. Montaner, 2000 .

A pilot study of hydroxyurea among patients with advanced human immunodeficiency virus (HIV) disease receiving chronic didanosine therapy: Canadian HIV trials network protocol 080.

J. Montaner, M. Schechter, B. Conway, 1997, The Journal of infectious diseases.

Impact of HIV infection on mortality in a cohort of injection drug users.

M. Schechter, S. Currie, M. Tyndall, 2001 .

Incidence of morphological and lipid abnormalities: gender and treatment differentials after initiation of first antiretroviral therapy.

J. Singer, R. Hogg, J. Montaner, 2002, International journal of epidemiology.

Antiretroviral treatment patterns and incident HIV-associated morphologic and lipid abnormalities in a population-based chort.

J. Singer, R. Hogg, J. Montaner, 2002, Journal of acquired immune deficiency syndromes.

Suppression of plasma virus load below the detection limit of a human immunodeficiency virus kit is associated with longer virologic response than suppression below the limit of quantitation.

P. Harrigan, R. Hogg, J. Montaner, 1999, The Journal of infectious diseases.

Adherence to triple therapy and viral load response.

R. Hogg, J. Montaner, M. O’Shaughnessy, 2000, Journal of acquired immune deficiency syndromes.

Incarceration, Addiction and Harm Reduction: Inmates Experience Injecting Drugs in Prison

M. Schechter, M. O’Shaughnessy, P. Spittal, 2005, Substance use & misuse.

Social determinants predict needle-sharing behaviour among injection drug users in Vancouver, Canada.

M. Schechter, C. Archibald, M. Ofner, 1997, Addiction.

Alcohol use and incarceration adversely affect HIV-1 RNA suppression among injection drug users starting antiretroviral therapy

B. Yip, R. Hogg, J. Montaner, 2003, Journal of Urban Health.

Factors associated with the response to antiretroviral therapy among HIV-infected patients with and without a history of injection drug use.

R. Hogg, J. Montaner, S. Strathdee, 2001, AIDS.

Modelling the impact of HIV disease on mortality in gay and bisexual men.

R. Hogg, J. Montaner, M. Schechter, 1997, International journal of epidemiology.

Factors Associated with Willingness to Participate in HIV Vaccine Trials Among HIV-Negative Injection Drug Users and Young Gay and Bisexual Men

R. Hogg, M. Schechter, S. Strathdee, 2000, AIDS and Behavior.

Patterns of sexual behavior and condom use in a cohort of homosexual men.

M. Schechter, M. O’Shaughnessy, K J Craib, 1988, American journal of public health.

Mitochondrial:nuclear DNA ratios in peripheral blood cells from human immunodeficiency virus (HIV)-infected patients who received selected HIV antiretroviral drug regimens.

P. Harrigan, B. Yip, R. Hogg, 2003, The Journal of infectious diseases.

How otherwise dedicated AIDS prevention workers come to support state-sponsored shortage of clean syringes in Vancouver, Canada

M. Schechter, E. Wood, M. O’Shaughnessy, 2004 .

An external evaluation of a peer-run “Unsanctioned” syringe exchange program

M. Schechter, E. Wood, T. Kerr, 2003, Journal of Urban Health.

The Potential Public Health and Community Impacts of Safer Injecting Facilities: Evidence From a Cohort of Injection Drug Users

R. Hogg, M. Schechter, E. Wood, 2003, Journal of acquired immune deficiency syndromes.

Antiretroviral medication use among injection drug users: two potential futures

Julio S. G. Montaner, R. Hogg, J. Montaner, 2000, AIDS.

Impact of HIV Infection on Mortality in a Cohort of Injection Drug Users

M. Schechter, S. Currie, M. Tyndall, 2001, Journal of acquired immune deficiency syndromes.

Highly Active Antiretroviral Therapy: Physician Experience and Enhanced Adherence to Prescription Refill

B. Yip, R. Hogg, J. Montaner, 2002, Antiviral therapy.

Impact of supply-side policies for control of illicit drugs in the face of the AIDS and overdose epidemics: investigation of a massive heroin seizure.

Evan Wood, Kathy Li, Martin T Schechter, 2003, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

The changing spectrum of AIDS index diseases in Canada

R. Hogg, J. Montaner, M. Schechter, 1994, AIDS.

Depressive Symptoms Decline Among Persons on HIV Protease Inhibitors

Julio S. G. Montaner, R. Hogg, E. Wood, 2000, Journal of acquired immune deficiency syndromes.

Prevalence of primary HIV drug resistance among seroconverters during an explosive outbreak of HIV infection among injecting drug users.

P. Harrigan, C. Alexander, J. Montaner, 1999, AIDS.

"Being dealt with as a whole person." Care seeking and adherence: the benefits of culturally competent care.

R. Hogg, M. O’Shaughnessy, A. Schilder, 2001, Social science & medicine.

Isolation of drug‐resistant variants of HIV‐1 from patients on long‐term zidovudine therapy

K. Gelmon, J. Montaner, M. Wainberg, 1989, AIDS.

Industry-sponsored clinical research: a double-edged sword

J. Montaner, M. Schechter, M. O’Shaughnessy, 2001, The Lancet.

Do needle exchange programmes increase the spread of HIV among injection drug users?: an investigation of the Vancouver outbreak.

M. Schechter, S. Strathdee, S. Currie, 1999, AIDS.

Determinants of HIV seroconversion in drug users during a period of rising prevalence in Vancouver

M. Schechter, C. Archibald, M. Ofner, 1997 .

Antiretroviral concentrations in untimed plasma samples predict therapy outcome in a population with advanced disease.

P. Harrigan, B. Yip, R. Hogg, 2003, The Journal of infectious diseases.

Incidence of hepatitis C virus infection among injection drug users during an outbreak of HIV infection.

M. Schechter, S. Strathdee, S. Currie, 2001, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

Monoclonal idiotypic and anti-idiotypic antibodies to human immunodeficiency virus type 1 envelope glycoprotein.

M. O’Shaughnessy, S. Faucher, J. Hamel, 1991, The Journal of general virology.

Incidence of hepatitis C virus infection among injection drug users during an outbreak of HIV infection

M. Schechter, S. Strathdee, S. Currie, 2022 .

Primary lamivudine resistance in acute/early human immunodeficiency virus infection.

J. Montaner, D. Rouleau, B. Conway, 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Satellite Needle Distribution Among Injection Drug Users: Policy and Practice in Two Canadian Cities

M. Schechter, J. Bruneau, M. Tyndall, 2002, Journal of acquired immune deficiency syndromes.

Factors associated with frequent needle exchange program attendance in injection drug users in Vancouver, Canada.

M. Schechter, C. Archibald, M. Ofner, 1998, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

Extent to which low-level use of antiretroviral treatment could curb the AIDS epidemic in sub-Saharan Africa

Evan Wood, Paula Braitstein, Martin T Schechter, 2000, The Lancet.

The impact of antiretroviral therapy on AIDS survival observed in a province-wide drug treatment programme.

R. Hogg, J. Montaner, M. Schechter, 1998, International journal of STD & AIDS.

Nature, time course and dose dependence of zidovudine‐related side effects: results from the Multicenter Canadian Azidothymidine Trial

K. Gelmon, J. Montaner, M. Wainberg, 1989, AIDS.

Impaired Virologic Response to Highly Active Antiretroviral Therapy Associated With Ongoing Injection Drug Use

B. Yip, R. Hogg, J. Montaner, 2003, Journal of acquired immune deficiency syndromes.

Expanding access to HIV antiretroviral therapy among marginalized populations in the developed world.

R. Hogg, J. Montaner, D. Bangsberg, 2003, AIDS.

Cessation of zidovudine therapy may lead to increased replication of HIV-1.

K. Gelmon, J. Montaner, M. Wainberg, 1989, Journal of the American Medical Association (JAMA).

Characterization of Reverse Transcriptase Activity and Susceptibility to Other Nucleosides of AZT‐Resistant Variants of HIV‐1

J. Montaner, M. Wainberg, J. Ruedy, 1990, Annals of the New York Academy of Sciences.

Interferon inhibition of DNA synthesis and cell division.

M. O’Shaughnessy, S. H. Lee, K. Rozee, 1972, Canadian journal of microbiology.

The effect of cigarette smoking on lymphocyte subsets and progression to AIDS in a cohort of homosexual men.

J. Montaner, M. Schechter, R. Voigt, 1992, Clinical and investigative medicine. Medecine clinique et experimentale.

The Vancouver Lymphadenopathy-AIDS Study: 4. Effects of exposure factors, cofactors and HTLV-III seropositivity on number of helper T cells.

Ccfp, B. Wiggs, M. Schechter, 1985, Canadian Medical Association journal.

Intentional Nonadherence Due to Adverse Symptoms Associated With Antiretroviral Therapy

J. Singer, R. Hogg, J. Montaner, 2002, Journal of acquired immune deficiency syndromes.

The relationship between adenosine 3':5'-cyclic monophosphate (cAMP) and interferon activity in mouse cells.

R. B. Stewart, M. O’Shaughnessy, R. Stewart, 1980, The Journal of general virology.

Accuracy of a saliva test for HIV antibody.

J. Montaner, S. Marion, M. O’Shaughnessy, 1995, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

Effect of Low‐Dose Gamma Radiation on HIV Replication in Human Peripheral Blood Mononuclear Cells

B. Conway, C. Greenstock, J. Montaner, 1996, Photochemistry and photobiology.

Modern Antiretroviral Therapy Improves Life Expectancy of Gay and Bisexual Males in Vancouver’s West End

R. Hogg, K. Bartholomew, E. Wood, 2000, Canadian journal of public health = Revue canadienne de sante publique.

Clinical correlates of in vitro HIV‐1 resistance to zidovudine. Results of the Multicentre Canadian AZT Trial

J. Singer, J. Montaner, M. Wainberg, 1993, AIDS.

Determinants of sexual risk-taking among young HIV-negative gay and bisexual men.

R. Hogg, J. Montaner, M. Schechter, 1998, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

Sources and Magnitude of Intralaboratory Variability in a Sequence-Based Genotypic Assay for Human Immunodeficiency Virus Type 1 Drug Resistance

P. Harrigan, B. Wynhoven, M. O’Shaughnessy, 2003, Journal of Clinical Microbiology.

"Discordant" increases in CD4 cell count relative to plasma viral load in a closely followed cohort of patients initiating antiretroviral therapy.

B. Yip, R. Hogg, J. Montaner, 2002, Journal of acquired immune deficiency syndromes.

Adherence to Antiretroviral Therapy and Cd4 T-Cell Count Responses among HIV-Infected Injection Drug Users

B. Yip, R. Hogg, J. Montaner, 2004, Antiviral therapy.

Modest Decreases in Nnrti Susceptibility Do Not Influence Virological Outcome in Patients Receiving Initial Nnrti-Containing Triple Therapy

K. Hertogs, W. Verbiest, B. Larder, 2002, Antiviral therapy.

Predictors of early hospital readmission in HIV-infected patients with pneumonia

M. Schechter, A. Anis, A. Palepu, 2003, Journal of General Internal Medicine.

Determinants of HIV seroconversion in injection drug users during a period of rising prevalence in Vancouver.

M. Schechter, C. Archibald, M. Ofner, 1997, International journal of STD & AIDS.

The effect of zidovudine on platelet count in HIV-infected individuals.

K. Gelmon, M. Wainberg, J. Ruedy, 1990, Journal of acquired immune deficiency syndromes.

Determinants of geographic mobility among participants in a population-based HIV/AIDS drug treatment program.

R. Hogg, J. Montaner, M. Schechter, 2000, Health & place.

Susceptibility to AIDS progression appears early in HIV infection

J. Montaner, M. Schechter, M. O’Shaughnessy, 1990, AIDS.

Prevalence and Response to Antiretroviral Therapy of Non-B Subtypes of HIV in Antiretroviral-Naive Individuals in British Columbia

P. Harrigan, C. Alexander, J. Montaner, 2002, Antiviral therapy.

Gay life expectancy revisited.

R. Hogg, J. Montaner, M. Schechter, 2001, International journal of epidemiology.

Use of the Markov model to estimate the waiting times in a modified WHO staging system for HIV infection.

J. Montaner, M. Schechter, M. O’Shaughnessy, 1995, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

A reality check: the cost of making post-exposure prophylaxis available to gay and bisexual men at high sexual risk.

R. Hogg, J. Montaner, K. Bartholomew, 2000, AIDS.

A comparison of the new Federal Guidelines regulating supervised injection site research in Canada and the Tri-Council Policy Statement on Ethical Conduct for Research Involving Human Subjects

M. Schechter, E. Wood, T. Christie, 2004 .